Evidence for additional adjuvant treatment in the hormone receptor-positive HER2-negative cancers with residual disease is lacking as the penelopeB trial did not show improved invasive DFS with the addition of the CDK4/6 inhibitor palbociclib [30]. Here, ERBB2 is linked to cancer.